Proximity of magnesium exposure to delivery and neonatal outcomes


      In infants delivered preterm, magnesium sulfate reduces cerebral palsy in survivors. The benefit of magnesium given remote from delivery is unclear.


      Our objective was to evaluate the association of time from last exposure to magnesium with cerebral palsy.

      Study Design

      This was a secondary analysis of a multicenter trial evaluating magnesium for neuroprotection. For this study, we included women with live, nonanomalous, singleton gestations who received magnesium. Pregnancies with missing information at the 2 year follow-up were excluded. Women were divided into 2 groups based on exposure timing: last infusion of magnesium <12 hours and last infusion of magnesium ≥12 hours prior to delivery. The primary outcome was cerebral palsy of any severity at 2 years of life. Secondary outcomes were moderate/severe cerebral palsy and moderate/severe cerebral palsy or death. A χ2 test, Student t test, and Mann-Whitney U test were used for bivariate associations. We fit a multivariable logistic regression model to adjust for confounders.


      A total of 906 infants were analyzed. Five hundred sixty-eight were last exposed to magnesium <12 hours prior to delivery and 338 were last exposed ≥12 hours. Cerebral palsy occurred in 28 offspring (3%), 2.3% of those last exposed <12 hours vs 4.4% last exposed ≥12 hours prior to delivery (P = .07). On adjusted analyses, last exposure to magnesium <12 hours prior to delivery was associated with a significant reduction in cerebral palsy compared with last exposure ≥12 hours (adjusted odds ratio, 0.41, 95% confidence interval, 0.18–0.91, P = .03). There was no difference in secondary outcomes.


      Exposure to magnesium proximal to delivery (<12 hours) is associated with a reduced odds of cerebral palsy compared with more remote exposure. This highlights the importance of the timing of magnesium for neuroprotection for women at risk of preterm delivery.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Centers for Disease Control and Prevention. Data and statistics for cerebral palsy. Available at: Accessed June 12, 2015.

        • Rouse D.J.
        • Hirtz D.G.
        • Thom E.
        • et al.
        A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.
        N Engl J Med. 2008; 359: 895-905
        • American College of Obstetricians and Gynecologists
        Magnesium sulfate before anticipated preterm birth for neuroprotection. Committee opinion no. 455.
        Obstet Gynecol. 2010; 116: 669-671
        • Crowther C.A.
        • Hiller J.E.
        • Doyle L.W.
        • Haslam R.R.
        Australasian Collaborative Trial of Magnesium Suphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial.
        JAMA. 2003; 290: 2669-2676
        • Marret S.
        • Marpeau L.
        • Zupan-Simunek V.
        • et al.
        Magnesium sulphate given before very preterm birth to protect infant brain: the randomized controlled PREMAG trial.
        BJOG. 2007; 114: 310-318
        • Mittendorf R.
        • Dambrosia J.
        • Pryde P.G.
        • et al.
        Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes.
        Am J Obstet Gynecol. 2002; 186: 1111-1118
        • McPherson J.A.
        • Rouse D.J.
        • Grobman W.A.
        • Palatnik A.
        • Stamilio D.M.
        Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes.
        Obstet Gynecol. 2014; 124: 749-755